TNFRSF17 and Miyoshi myopathy: B-lineage monoclonal antibodies (anti-CD20: rituximab, ofatumumab, and obinutuzumab; anti-CD38: isatuximab and daratumumab; anti-CD30: brentuximab vedotin; anti-CD52: alemtuzumab; anti-CD269: belantamab mafodotin; or anti-CD319: elotuzumab) were used in three studies in CLL (54, 59, 66), two in MM (68, 91), and seven in NHL (110, 113, 122, 124, 127, 128, 134) as monotherapy.